Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSS

Mellen Center for MS Treatment and Research U10, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Journal of the neurological sciences (Impact Factor: 2.26). 12/2008; 282(1-2):106-11. DOI: 10.1016/j.jns.2008.11.018
Source: PubMed

ABSTRACT Gray matter (GM) pathology is an important component of the multiple sclerosis (MS) disease process. Accelerated gray matter atrophy has been observed in MS patients, but its relationship to neurological disability is not defined. This study was done to determine the relationship between whole brain, GM, and white matter (WM) atrophy and MS disability progression.
Patients with MS and Clinically Isolated Syndromes (CIS), and age- and gender-matched healthy controls were entered into an observational protocol. Baseline brain parenchymal fraction (BPF), GM fraction, and WM fraction, and change over 4 years were correlated with sustained disability progression over the entire study duration. Disability progression was measured using the Multiple Sclerosis Functional Composite (MSFC) and the Expanded Disability Status Scale (EDSS).
Seventy MS and CIS patients and 17 HCs were studied for an average of 6.6 years (range, 3.6-7.8 years). At the final visit, 7 patients were classified as CIS, 36 as relapsing-remitting MS (RRMS), and 27 as secondary progressive MS (SPMS). Baseline whole brain, GM, and WM atrophy predicted EDSS >6.0 at the last study visit. Twenty-one (33%) patients worsened using the EDSS to define disability progression; 29 (46%) worsened using MSFC to define disability progression. Patients with MSFC progression had significantly higher GM atrophy rates compared with patients who were stable on MSFC. White matter atrophy was similar in patients with and without disability progression. Atrophy rates were not different in patients with or without disability progression defined using EDSS.
Whole brain, GM, and WM atrophy predicted MS disability progression observed over the next 6.6 years. Gray matter atrophy rates over 4 years correlated with disability progression measured with the MSFC, but not EDSS. This indicates that MSFC defined disability progression is more closely linked to brain atrophy than EDSS defined disability progression, and provides important new insight into the poor correlation between MRI and clinical disability in MS. The findings confirm the clinical relevance of gray matter atrophy in MS.

Download full-text


Available from: Elizabeth Fisher, Jun 16, 2014
  • Source
    • "However, TG6 is found exclusively in neural tissue, and autoantibodies against this enzyme weren't assayed for. There is also no direct correlation between gluten sensitivity and prevalence of multiple sclerosis (Paul et al. 2008), but some studies show an increased prevalence of anti-gluten antibodies in multiple sclerosis (Fischer et al. 2008, Rudick et al. 2009, Lindeberg, 2010, Ranohoff and Lucinetti 2011). A causal loop diagram for the effect of gluten and dairy products on the blood brain barrier and the creation of immuno-provocative substances is shown in Figures 7 and 8The substances interleukin-1β and TNF-α are produced from omega-6. "
    Model-based Management. Systems Dynamic Society, St. Gallen, Switzerland; 07/2013
  • Source
    • "The EDSS correlation results imply that brain atrophy and the NAWM burden of disease are better predictors of disability. It is known from previous studies that brain atrophy (PVF) correlates with EDSS, although the strength of this correlation has ranged from weak to moderate (Furby et al., 2008; Kalkers et al., 2002; Martola et al., 2007, 2010; Rudick et al., 2009). However, our work is the first to show that a quantitative myelin water fraction measure derived from mcDESPOT acquisition adds statistically significant patient disability predictive value on top of PVF, as evidenced by its inclusion in the optimal multiple linear regression model. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent multiple sclerosis (MS) MRI research has highlighted the need to move beyond the lesion-centric view and to develop and validate new MR imaging strategies that quantify the invisible burden of disease in the brain and establish much more sensitive and specific surrogate markers of clinical disability. One of the most promising of such measures is myelin-selective MRI that allows the acquisition of myelin water fraction (MWF) maps, a parameter that is correlated to brain white matter (WM) myelination. The aim of our study was to apply the newest myelin-selective MRI method, multi-component Driven Equilibrium Single Pulse Observation of T1 and T2 (mcDESPOT) in a controlled clinical MS pilot trial. This study was designed to assess the capabilities of this new method to explain differences in disease course and degree of disability in subjects spanning a broad spectrum of MS disease severity. The whole-brain isotropically-resolved 3D acquisition capability of mcDESPOT allowed for the first time the registration of 3D MWF maps to standard space, and consequently a formalized voxel-based analysis of the data. This approach combined with image segmentation further allowed the derivation of new measures of MWF deficiency: total deficient MWF volume (DV) in WM, in WM lesions, in diffusely abnormal white matter and in normal appearing white matter (NAWM). Deficient MWF volume fraction (DVF) was derived from each of these by dividing by the corresponding region volume. Our results confirm that lesion burden does not correlate well with clinical disease activity measured with the extended disability status scale (EDSS) in MS patients. In contrast, our measurements of DVF in NAWM correlated significantly with the EDSS score (R2=0.37; p<0.001). The same quantity discriminated clinically isolated syndrome patients from a normal control population (p<0.001) and discriminated relapsing-remitting from secondary-progressive patients (p<0.05); hence this new technique may sense early disease-related myelin loss and transitions to progressive disease. Multivariate analysis revealed that global atrophy, mean whole-brain myelin water fraction and white matter atrophy were the three most important image-derived parameters for predicting clinical disability (EDSS). Overall, our results demonstrate that mcDESPOT-defined measurements in NAWM show great promise as imaging markers of global clinical disease activity in MS. Further investigation will determine if this measure can serve as a risk factor for the conversion into definite MS and for the secondary transition into irreversible disease progression.
    NeuroImage 09/2011; 59(3):2670-7. DOI:10.1016/j.neuroimage.2011.08.052 · 6.36 Impact Factor
  • Source
    • "Transformation to a z-score allows comparison of an individual to the average population (internal or external reference population). The MSFC has been validated against the EDSS, MRI and quality of life measures demonstrating its validity, reliability and sensitivity to change [Rudick et al. 2009a; Pascual et al. 2008; Cohen et al. 2001, 2000; Kalkers et al. 2001, 2000; Miller et al. 2000; Cutter et al. 1999]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease with both clinical and pathological heterogeneity. The complexity of the MS population has offered challenges to the measurement of MS disease progression in therapeutic trials. The current standard clinical outcome measures are relapse rate, Expanded Disability Severity Scale (EDSS), and the MS Functional Composite (MSFC). These measures each have strengths and some weakness. Two additional measures, the six-minute walk and accelerometry, show promise in augmenting current measures. MS therapeutics is a quickly advancing field which requires sensitive clinical outcome measures that can detect small changes in disability that reliably reflect long-term changes in sustained disease progression in a complex population. A single clinical outcome measure of sustained disease progression may remain elusive. Rather, an integration of current and new outcome measures may be most appropriate and utilization of different measures depending on the MS population and stage of the disease may be preferred.
    Therapeutic Advances in Neurological Disorders 07/2010; 3(4):229-39. DOI:10.1177/1756285610374117
Show more